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Summary 
 
Background Topical imiquimod is sometimes used for lentigo maligna (LM) in 
situ melanoma instead of surgery, but frequency of cure is uncertain. Pathological  
complete regression (pCR) is a logical surrogate marker  for  cure  after  imiqui-  
mod, although residual LM and atypical melanocytic hyperplasia may not be reli-   
ably distinguished. A trial  comparing  imiquimod  vs.  surgery  might  be  
justified  by a high imiquimod pCR    rate. 
Objectives  Primary: to estimate the pCR rate for LM following imiquimod.   
Second- 
ary: to assess the accuracy of prediction of pCR, using clinical complete 
regres- sion (cCR) plus negative post-treatment biopsies, tolerability, resource 
use, patients’ preferences and induced melanoma immunity. 
Methods  This  was  a  single-arm  phase  II  trial  of  60  imiquimod        
applications 
over 12 weeks for LM then radical resection. A pCR rate ≥ 25 out of 33 would 
reli- ably discriminate between pCR rates < 60% and ≥ 85%. Clinical response 
was assessed and biopsies taken after imiquimod. Patients recorded adverse 
events in diaries. Patient preference was measured after surgery using a standard 
gamble tool. Results The pCR rate was 10 of 27 (37%, 95% confidence interval 
19–58%).  The  rate of cCR plus negative biopsies was 12 of 28, of whom seven 
of 11 had pCR       on subsequent surgery. The median dose intensity was  86·7%.  
Of  the  16  sur-  veyed patients, eight preferred  primary  imiquimod  over  
surgery  if  the  cure  rate for imiquimod was 80%, and four of 16 if it was ≤ 
40%. 
Conclusions The pCR rate was insufficient to justify phase III investigation of imi- 
quimod vs. surgery. Clinical complete response and negative targeted 
biopsies left uncertainty regarding pathological clearance. Some patients 
would trade less aggressive treatment of LM against efficacy. 
 
 
 
 
 
 
  
 
 
 
 
Lentigo maligna (LM) in situ melanoma characteristically pre- 
sents as a slowly developing brown or dark brown macule on 
chronically sun-exposed skin in  people  aged  > 50  years.  In  
the U.K. guidelines, complete surgical resection is recom-  
mended with curative intent.1 Five per cent of patients with  
typical LM may actually have  early  invasive  melanoma,  and 
the risk of progression to invasive lentigo maligna melanoma 
(LMM) is poorly quantified.2 Reported outcomes following 
surgery vary, including a 30% probability of  recurrence  at  
66–98 months and a 1·5% probability  of  transformation  to  
LMM for 81 patients,3 a crude failure rate (recurrence plus 
incomplete excision) of eight of 102 following resection exci-  
sion with  2-mm  margins,4  and  crude  recurrence  rates  of  
16  of 269 (5·9%) following wide local excision and three of 
154 (1·9%)  following  Mohs  micrographic  surgery.5  LM  
occurs most frequently on the head and neck, so surgery can 
cause significant functional and cosmetic disability  and,  in  
some  cases, might not be   feasible. 
In 2001, a U.K. survey showed that the most widely used 
treatments for LM were surgery, cryotherapy,  radiotherapy 
and observation, in that order, with nonsurgical approaches 
possibly associated with higher recurrence rates and  used 
more for patients aged > 70 years.6 Radiotherapy may have 
a place in LM management, with the aim of trading less 
inva- sive intervention and better function and cosmesis 
against a possibly higher risk of recurrence or progression 
to melanoma.7–10 No trials have been undertaken comparing 
the outcomes of surgery and radiotherapy or other 
nonsurgical treatments.11 
Imiquimod is a synthetic imidazoquinoline nucleoside 
ana- logue available as a 5% strength topical formulation, 
with low systemic availability. Skin application induces 
local inflamma- tion with intensity related to the frequency 
of application. The use of topical imiquimod as a 
nonsurgical treatment for LM has increased following an 
initial case report in 2000 of dis- ease control for 9 months 
after treatment for 7 months.12 Treatment duration is not 
defined, but 12 weeks is widely used;13 any benefit of 
longer treatment is unclear. An effect against LM has been 
confirmed in subsequent case reports and small 
uncontrolled trials, and in a systematic review,14 with 
response rates of 77–90%. These studies lacked long-term 
fol- low-up to substantiate disease control and post-
treatment his- tology: the majority of cases involved biopsy 
only, with the possibility of sampling error.15–22 One small 
study used com- plete surgical excision following 
imiquimod treatment, and reported complete response in 
four of six patients recruited.23 A recent retrospective series 
reported recurrence of LM follow- ing imiquimod alone in 
six of 22 patients vs. two of 36 hav- ing surgery plus 
imiquimod with a mean follow-up of around 40  months.13 
The routine use of imiquimod as primary therapy for LM 
requires proof of efficacy in a large trial compared with the 
outcomes of surgical excision. We reasoned that, to justify 
this investment, imiquimod treatment should be shown to 
have a high probability of achieving pathological complete 
response (pCR). Patients and clinicians might take into 
account the probability of cure with imiquimod and 
avoiding surgery for    a premalignant condition, assuming 
progression is susceptible to surveillance. We surveyed 
U.K. dermatologists’ opinions regarding what threshold of 
pCR rate would justify routine  use of imiquimod instead 
of surgery. We then designed a sin- gle-arm trial to justify 
progression to a  larger  randomized trial. We sought 
opinion from trial participants regarding what threshold of 
efficacy they would trade against avoiding sur- gery, using 
a structured questionnaire. 
 
Patients and methods 
 
Participants 
This study was coordinated through the Nottingham 
Clinical Trials Unit, and approved by Nottingham Research 
Ethics Committee 2 and eight hospitals recruited between 
October 2010 and August 2011. The trial was registered 
with clinical- trials.gov identifier NCT01161888. 
To be eligible, patients had to give informed written con- 
sent, have a clinical diagnosis of primary untreated LM (ac- 
quired pigmented macule present for > 12 months, no  
change in skin surface texture or contour, no palpability, 
diameter > 10 mm, sited on the head or neck) and histologi- 
cally confirmed LM without invasive melanoma in one  or 
more 4-mm punch biopsies from the darkest area, reported   
by a pathologist member of a recognized National Health 
Ser- vice skin cancer multidisciplinary team. The LM had 
to be suitable for complete surgical excision using a 5-mm 
lateral margin, and to be easily definable visually around its 
entire circumference. Patients had to be aged > 45 years, fit, 
and willing for surgery, without coexisting or adjacent 
melanoma or nonmelanoma skin cancer that might 
compromise study treatment; neither pregnant nor 
breastfeeding; without hyper- sensitivity to imiquimod or 
excipients; not taking immuno- suppressive medication and 
not participating in another intervention study. 
 
Treatment and follow-up 
The trial interventions and investigations are detailed in 
Fig- ure 1. The pretreatment lesion was photographed, 
tattooed at 360, 90, 180 and  270 degrees, outlined  in ink 
and traced  on  a   transparency.   Training   in   mapping   
and   tattooing was 
 
 IMIQUIMOD TREATMENT: Apply to visible 
skin + 2-cm margin normal skin, wash off 
after 8 h (overnight)  5 days/week. 
Escalate to 7 days/week if well tolerated. 
De-escalate to 3 days/week for intolerable 
inflammatory reactions. Suspend for 7 days 
at dermatologist’s discretion for poor 
tolerance. 
MAP 2: Use tattoos and map 1 to define 
pretreatment lesion. Draw round new 
pigmentation. Add 5-mm margin to define 
excision  area.  Trace  onto transparent sheet 
Patients with clinical diagnosis of  LM Identified 157 
Histological confirmation of LM 
 
Consent Enrolled 30 a, b 
Screen for eligibility 
 
Week 1–12 imiquimod treatment. Daily 
diaries of adverse events and compliance, 
and weekly acceptability. 
 
Week 22–24 clinical assessment of 
response. 
Biopsies from normal skin, residual 
pigmentation and new pigmentation. 
Surgical excision of entire mapped  lesion. 
Surgical excision 27 f 
Assess pathological response in  biopsies 
and surgical specimen. Report to local 
investigator. 
 
Week 36 – complete survey of patient’s 
treatment preference 
MAP 1: Draw round perimeter of lesion. 
Tattoo edge at 4 compass points. Trace on 
transparent  sheet 
Blood sample 
Blood sample 
CENTRAL PATHOLOGICAL REVIEW: Single 
H&E section of pre and post-treatment 
biopsy and 2-mm sections through whole 
surgical specimen and post-treatment 
biopsies. 
Completed questionnaire 16 g 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treated 29 c 
Continued on-trial 28 d 
Dose intensity e 
Median 87%, IQR  71–
111%, 
range 33–137% 
  
 
 
 
 
 
Fig 1. Trial design and recruitment. The sample constituted 28 patients evaluated on an intent-to-treat basis and 27 treated patients with 
post- treatment surgical specimens. (a) Seventy-five patients were ineligible, most commonly because of a lentigo maligna (LM) size < 10 
mm, invasive or recurrent disease, not on head or neck, LM histology not conclusive, steroid treatment, ill-defined lesion, inadequate 
surgical clearance or LM present < 12 months. (b) Fifty-two patients declined trial entry; the most common reasons were burden of 
travelling (10) or time involved (15), delay in surgery (13) and concerns over side-effects (three) or lack of efficacy (two) of imiquimod. (c) 
One patient withdrew consent before starting imiquimod. (d) One patient withdrew consent after 5·3 weeks of treatment. (e) Dose  intensity  
was  the  number  of  imiquimod  applications as a proportion of the expected 60 applications over 12 weeks. (f) One treated patient 
declined surgery after imiquimod. (g) The questionnaire was completed by the first 16 patients on the trial. H&E, haematoxylin and eosin; 
IQR, interquartile  range. 
 
provided. Patients applied imiquimod (Aldara®; Meda 
Pharma- ceuticals Ltd, Bishops Stortford, U.K.) 5 days per 
week to the visible lesion plus a 2-cm margin of normal 
surrounding skin for approximately 8 h (overnight). It was 
then  washed  off with soap and water as defined in the 
patient information leaf- let. After 12 weeks of treatment, 
lesions were remapped, biopsied and excised with central 
pathological reporting. The User Opinion Questionnaire 
was undertaken 12 weeks post- surgery by the first 16 
patients. 
 
Outcome measures 
The primary outcome measure was pCR, defined as the 
absence of LM in both post-treatment biopsies and resected 
LM. Imiquimod is an experimental treatment in which post-
treatment biopsies would be part of the assessment of 
clearance. Resection is the standard of care and, in this trial, 
permits assessment of LM clearance in the whole lesion. 
Other pathological outcomes were partial regression (pPR, 
atypical melanocytes present in the epidermis with 
abnormal distribu- tion and number, but insufficient 
features to define LM), no change (presence of LM) or 
progressive disease (invasive melanoma). 
Clinical outcomes were complete regression (cCR, 
complete disappearance of abnormal pigmentation), partial 
regression (cPR, reduction in size of pigmented area or 
obvious reduc- tion in its intensity), no change (appearance 
identical to that pretreatment) and progressive disease 
(increased size or inten- sity of pigmentation or 
development of a papule or nodule within LM). Targeted 
biopsies were scored as for the resection specimen, detailed 
above. For each individual, the prediction of pCR using 
clinical examination of the mapped regions (weeks 22–24) 
plus targeted presurgical biopsies was com- pared with the 
pathological response in the whole post-treat- ment resected 
lesion, including any LM outside the clinically mapped 
margins of disease. 
Patients kept weekly diaries through 12 weeks of 
treatment of adverse reactions, numbers of treatments, 
treatment accept- ability on a visual analogue scale and 
reasons for treatment withdrawal. The number of 
consultations was  recorded. 
Following surgery, the participants completed  a  question-  
naire selecting between ‘I want to have imiquimod as first 
treatment’ vs. ‘I want to have surgery now’ for 15 hypotheti- 
cal trial results ranging from ‘imiquimod cures 100% of peo- 
ple; surgery cures 95% of people’ to ‘imiquimod cures 10%   
of  people;  surgery  cures  95%  of  people’.  The    
explanation 
  
 
included that imiquimod treatment included surveillance 
and deferred surgery in the event of  progression. 
Whole-blood samples (40 mL) were harvested  before  and  
after imiquimod treatment and sent by first-class post to the 
Human Biomaterials Resource Centre, Birmingham, where 
peripheral blood mononuclear cells were  isolated  by  
differen- tial centrifugation and cryopreserved in the vapour 
phase of nitrogen. Circulating T-lymphocyte responses against 
melano-  cyte differentiation antigens melan A,  gp100  and  
tyrosinase,  and against cancer testis antigens MAGE A1, 
MAGE A3 and NY-ESO-1 were measured using an ex vivo 
ELIspot  assay,24 using overlapping peptides  covering  the  
whole  of  each  antigen. 
 
Statistical design and  analysis 
In 2009 all consultant members of the British Association of 
Dermatologists were asked to mark on a visual  analogue scale  
the pCR rate for imiquimod below which ‘I do not think that 
imiquimod has any potential at all to be used for primary 
treatment for lentigo maligna’ and the pCR rate above which    
‘I would be persuaded that imiquimod  definitely  should  be 
used in the primary treatment of lentigo   maligna’. 
This was a  single-arm phase II trial  with a sample  size of   
33, requiring pCR  in  ≥ 25  participants  to  justify  
progression to  phase  III   (A’Hern’s   method,   p0 = 60%,   
p1 = 85%, a = 5%, 1 — b = 95%).25 The bounds (p0  and  p1)  
were  derived from the upper quartile of pCR thresholds for 
derma- tologists responding to the two questions above. The  
recruit- ment  target  was  40 participants  to  account  for 
attrition. 
The primary intent-to-treat analysis included patients 
who discontinued imiquimod treatment early but proceeded 
to sur- gery as per the protocol requirements. The pCR rate 
for patients undergoing surgery after imiquimod was 
estimated with 95% confidence intervals (CIs). 
The accuracy of clinical assessment was reported as the pro- 
portion of cases where cCR plus negative biopsies correctly 
predicted pCR in the subsequent  surgical resection    
specimen. 
Imiquimod dose intensity was calculated from patient 
diary returns,  assuming  60  applications  (5 days  per  
week  for  12 weeks) to be  100%. 
Patients’ opinions are presented descriptively as the propor- 
tion of patients preferring imiquimod over surgery in relation      
to a range of hypothetical cure rates for imiquimod compared  
with a cure rate for surgery of 95%. Analyses were performed 
using Stata v12 (StataCorp, College Station, TX,  U.S.A.). 
 
Results 
Responses from 174 U.K. consultant dermatologists each 
iden- tified a lower pCR rate below which they considered 
imiqui- mod to have no potential to treat LM [median 40%, 
interquartile range (IQR) 30–60%] and an upper pCR rate 
above which they could definitely be persuaded of the 
poten- tial of imiquimod to treat LM (median 80%, IQR 
60–85%). This was interpreted as indicating that only 25% 
of   clinicians 
would reject further investigation of imiquimod as a 
treatment for LM even if the pCR rate was ≥ 60%, and only 
25% of clinicians would demand a pCR rate ≥ 85% to 
justify further investigation of imiquimod. We determined 
that an observed pCR threshold rate of ≥ 25 out of 33 
would reliably exclude a true pCR rate < 60% and be 
powered not to miss a true pCR rate ≥ 85% (see statistical 
design). 
Twenty-nine patients consented; one withdrew consent   and 
28 were evaluable. Their median age was 72 years (IQR 
65–79), 18 were male, the median size of LM was 14 mm 
(IQR 12–22; range 10–70) and lesions were located on the 
cheek (11), ear (four), forehead (four), nape of neck (one), 
nose (seven) and scalp (two). The median dose intensity 
over 12 weeks was 86·7%, including three patients stopping 
treat- ment early after 4, 8 and 11 weeks; 27 underwent 
surgical excision after imiquimod (Fig.  1). 
Twenty-seven patients were evaluable for the primary 
out- come. Ten achieved pCR (37%, 95% CI 19–58%). 
None showed LM at the surgical margins. The patients with 
pCR  had achieved imiquimod dose intensity below 
(seven) and above (three) the median of  86·7%. 
Central review of a single pretreatment section did not 
con- firm the diagnosis of LM in three patients: one with 
epidermal hyperpigmentation without melanocyte atypia; 
one with com- pound melanocytic naevus and one with 
pigmentation and elongated rete ridges without melanocyte 
atypia. The pCR rate was eight of 24 (33%, 95% CI 16–
55%) if these patients are excluded. However, priority was 
given to the fuller clinico- pathological diagnosis made by 
the multidisciplinary team at the site. 
Post-treatment resection specimens from a further nine 
patients were scored as pPR (abnormal features falling 
short of defining persistent LM – see methods), seven had 
definite residual LM in the resection specimen and one had 
evidence   of LMM. 
Clinical evaluation showed that 13 of 28 patients had 
com- plete disappearance of the LM after imiquimod (i.e.  
cCR; 46%, 95% CI 28–66%). Of these, on the post-
treatment biop- sies, 12 were negative for LM and one 
showed probable resid- ual LM. Thus clinical and targeted 
pathological evaluation yielded a response rate of 12 of 28 
(43%, 95% CI 24–63%). Of these 12, one declined 
resection, and seven of the remain- ing 11 (64%, 95% CI 
31–89%) had pCR on the resection specimen. Three of 15 
who did not achieve cCR were observed nonetheless to 
have pCR (Fig. 2). Regarding the three with pathological 
evidence falling short of LM on central review of  a  single  
diagnostic  slide,  the  outcomes  were cCR + pCR, cCR + 
pPR and cPR + pCR. 
Eleven of 29 patients (38%) had a severe local-site reaction 
over the study period; 10 (34%) had a moderate reaction and   
eight (28%) had mild or no reaction. This peaked at week 4,   
when 24%, 48% and 14% had mild, moderate and severe 
reactions, respectively. By week 12, 11% and 15% still had 
moderate or severe reactions, respectively. Nine of 19 patients 
(47%) having a moderate or severe local-site reaction  had  a  
pCR,  whereas  one  of  eight  patients  (13%)  with  mild  or    
no 
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Fig 2. Clinical and pathological responses 
of lentigo maligna (LM) to treatment. cCR, 
clinical complete response; cPR, clinical 
partial response (i.e. clinical evidence of 
improvement in the LM falling short of 
complete regression); cNC, clinical no 
change; cPD, clinical progressive disease; 
pCR, pathological complete response; 
pPR, pathological partial response; pNC, 
pathological no change (i.e. continuing 
evidence of LM in specimen); pPD, 
development of LMM; neg, negative; pos, 
positive. †marks a patient whose local 
diagnosis of LM was not confirmed on 
central review of the pretreatment biopsy; 
*marks a patient who declined resection of 
LM after imiquimod. 
 
 
reaction had a pCR. Scores for acceptability of imiquimod 
through 12 weeks of treatment were reported by 24 of 29 
patients. Dose reductions occurred in five of 12 reporting 
con- sistently good tolerance and eight of 12 reporting 
variably poor tolerance. 
There were 143 adverse events, of which 84 (59%) were 
definitely related to treatment. Medication was provided for 
117 (82%) adverse events, and 140 (98%) resolved. There  
was no additional health service use for 18 of 29 (62%), 
one unscheduled visit for eight (28%) and more than one 
unscheduled visit for three patients  (10%). 
Sixteen patients completed the treatment preference 
survey having experienced both treatments (Fig. 3). One 
expressed a strong preference for immediate surgery even 
with a hypo- thetical cure rate of 100% for imiquimod, and 
four strongly preferred imiquimod, tolerating hypothetical 
cure rates for imiquimod ≤ 40% vs. 95% for surgery. Half 
of the patients stated they would opt for surgery if the cure 
rate for imiqui- mod was ≤ 85%. 
Imiquimod might work by inducing immune responses 
against proteins characteristic of melanoma cells. We tested 
blood samples from 16 patients for such responses, of 
whom 11 had paired samples analysed about 3 months 
apart. Target proteins were a number of proteins 
characteristic of melanoma (melan A, gp100, tyrosinase, 
NY-ESO-1, MAGE A1 and MAGE A3) and, to confirm the 
patients’ cells were working, proteins were made by 
common infections (termed CEPT). Positive recognition of 
target proteins was defined conventionally as a number of 
reacting immune cells against target proteins that was more 
than double the background immune  reactivity. 
Twenty-seven samples from 16 patients were tested, and 
of these, 18 from 12 patients made a clear positive 
recognition  of 
 
  
 
 
 
         
 
 
 
Fig 3. User Opinion Questionnaire. Bar chart depicting the number 
of patients (y-axis) reporting preference for either surgery (red) or 
imiquimod (blue) for varying hypothetical imiquimod cures rates 
(x-axis) vs. a fixed surgical cure rate of 95%. Patients were 
surveyed having experienced both treatments. 
 
the CEPT control. Of the 18 samples with a positive CEPT 
response, three samples from two patients exhibited 
recognition of a melanoma antigen – both MAGE A1. Only 
six patients had paired samples with positive CEPT 
recognition on both samples, and of these, one of six (who 
had pPR and cPR) showed an amplified response over time, 
defined as the later recognition value being double that of 
the earlier reading. 
 
Discussion 
It is reasonable to try to spare patients surgery for LM; it 
can impair function and be disfiguring, and may not be 
feasible. 
Evaluable patients n = 28 
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Nonsurgical approaches need not equal surgery in efficacy, 
provided treatment failure could be recognized and surgery 
undertaken before progression to invasive melanoma. 
Imiquimod promotes an inflammatory state through the 
activation of macrophages and antigen-presenting cells via 
Toll-like receptor 7 signalling, and this localized 
inflammation can result in regression of neoplastic cells.26 
We undertook a single-arm phase II trial to determine 
whether investment is justified in a phase III trial 
comparing imiquimod with sur- gery. Clinical regression 
following imiquimod treatment can be followed by 
relapse.3 Therefore, pCR, measured by detailed histological 
examination of LM resected after imiquimod ther- apy, was 
selected as the surrogate outcome measure for possi- ble 
long-term disease control. 
The pCR rate of LM to imiquimod was estimated as 37% 
(10 of 27), with CIs indicating that a true pCR rate > 60%  
was unlikely and > 85% very unlikely. Even had accrual 
con- tinued to target, the highest possible observed pCR 
rate would have been 16 of 33, falling short of the 
preplanned efficacy threshold of 25 of  33. 
It is improbable that we missed a true effect. Firstly, 27 
of 29 patients completed the study and were available for 
analyses. Secondly, 21 of 29 patients had moderate or 
severe skin inflam- mation, similar to the imiquimod 
toxicity described in case reports of apparently successful 
imiquimod treatment. Thirdly, the median dose intensity 
was 87%, and reduced dose intensity across 12 weeks did 
not obviously associate with lower proba- bility of 
achieving pCR. Our pCR rate by detailed pathological 
examination is lower than the > 75% regression rate judged 
by clinical inspection and biopsies in a systemic review of 
pre- dominantly retrospective series and cases. Note that 
these case reports and series lacked consistent definition 
and were suscep- tible to selection and publication bias.14 
Recently, another trial observed a pCR rate of 20 of 38 
assessable patients with LM treated with imiquimod for 12 
weeks.19 A further study com- pared topical imiquimod 
with topical imiquimod plus topical tazarotene, followed by 
Mohs excision of the treatment site, with pCR rates of 57 
vs. 66%, respectively.18 
Can we rationally offer imiquimod as first-line treatment 
for LM, reserving surgery for treatment failure? Persistent 
or progressive clinical abnormality after imiquimod might 
rea- sonably be taken to indicate proceeding to surgery, 
because only three of 15 such patients had pCR on the 
resected speci- men. Conversely, apparent cCR and 
negative biopsy was an unreliable predictor of pCR, with 
only seven of 11 cases with cCR plus negative biopsies 
confirmed as pCR on examination of the excision 
specimen. We recognize that pPR as defined in this study is 
indistinguishable from actinic melanocytic hyper- plasia, 
likely to be present in chronically subdamaged skin.27 Thus 
there is uncertainty whether pPR induced by imiquimod 
might also be a marker for long-term clinical  remission, 
which was not addressed in our  study. 
The efficacy threshold to justify phase III evaluation had 
been selected to exclude, at the 5% probability level, 
proceed- ing to phase III despite a true pCR rate of < 60% 
and rejecting further investigation despite a true pCR rate > 
85%. These 
thresholds were based on a survey of a large group of U.K. 
dermatologists. However, reported opinions were  diverse. 
Only half would definitely reject imiquimod treatment even 
if the true pCR rate was < 40%, and one-quarter would 
have settled for a true pCR rate < 60% definitely to proceed 
to phase III. Offering imiquimod treatment for a 
premalignant condition, with surgery reserved for 
progression, is a credible strategy for some clinicians 
despite a low pCR rate.  How might patients view this 
issue? We surveyed the opinion of  the first 16 consecutive 
patients after each had experienced both imiquimod and 
surgery, and again observed diversity of opinion: four of 16 
would still have  opted  for  imiquimod even with the 
probability of cure ≤ 40%. However, we had not expected 
the very high early attrition on accrual, in which only one-
fifth of identified patients enrolled for the trial. This might 
cause bias favouring imiquimod because this attrition itself 
may reflect patients’ preference for surgery. 
Destroyed cells in a proinflammatory milieu might act as an 
autologous vaccination against  melanoma,  resulting  in  sys- 
temic immunity. However, we observed that our participants 
generally had a frequency of circulating activated T cells rec- 
ognizing melanoma differentiation or  cancer  germline  anti-  
gens below the limit of detection of the ex vivo ELIspot assay 
(around 50 per 106 peripheral blood mononuclear  cells)  even 
after imiquimod treatment.  A  larger  sample  would  be  
needed to estimate confidently the immune response  rate,  and  
this  would also require assays able to detect and measure 
lower- abundance  immune  reactivities. 
In summary, imiquimod causes local skin adverse 
reactions, which are variably tolerated by patients and can 
be managed by adjusting the frequency of applications. We 
estimated the pCR rate of LM to imiquimod to be 37%.  
This fell short  of our predefined end point that would 
justify progression to a randomized comparison vs. surgery, 
assuming that pCR is a prerequisite for long-term disease 
control. The uncertainty  over the interpretation of pPR and 
the possibility that imiqui- mod given for a longer duration 
might convert pPR to pCR might still justify such a trial. 
We observed that clearance of LM clinically and on 
targeted biopsies missed patients either in whom LM was 
pathologically persistent or in whom patho- logical 
persistence was, at best, uncertain. Based on this, with- out 
a larger long-term trial, the use of imiquimod cannot be 
recommended as standard first-line treatment for LM 
outside exceptional circumstances. 
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